Recombinant Human ARL4A protein

中文名： ADP核糖基化因子样蛋白4A(ARL4A)重组蛋白
别名： ARL4A；ARL4；ADP-ribosylation factor-like protein 4A

货号: PA1000-225DB

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	> 90 % SDS-PAGE.
种属	Human
靶点	ARL4A
Uniprot No	P40617
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-200aa
氨基酸序列	MGSSHHHHHHSSGLVPRGSHMGNGLSDQTSILSNLPSFQSFHIVILGLDC AGKTTVLYRLQFNEFVNTVPTKGFNTEKIKVTLGNSKTVTFHFWDVGGQE KLRPLWKSYTRCTDGIVFVVDSVDVERMEEAKTELHKITRISENQGVPVL IVANKQDLRNSLSLSEIEKLLAMGELSSSTPWHLQPTCAIIGDGLKEGLE KLHDMIIKRRKMLRQQKKKR
预测分子量	25 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是3篇关于ARL4A重组蛋白的相关文献概览：

1. **标题**：*ARL4A regulates glioma cell proliferation and invasion through the MAPK pathway*

**作者**：Chen Y, et al.

**摘要**：研究通过重组ARL4A蛋白体外实验，证明其过表达激活MAPK信号通路，促进胶质瘤细胞增殖和侵袭，提示其在肿瘤进展中的潜在作用。

2. **标题**：*Structural insights into the GTP-binding specificity of ARL4A*

**作者**：Zhang L, et al.

**摘要**：通过重组ARL4A蛋白的结晶与结构分析，揭示其GTP结合域的特异性构象变化，为理解其与小分子效应蛋白相互作用的机制提供结构基础。

3. **标题**：*Recombinant ARL4A protein promotes macrophage migration via CDC42 activation*

**作者**：Wang H, et al.

**摘要**：利用大肠杆菌表达系统纯化ARL4A重组蛋白，证实其通过激活CDC42信号通路增强巨噬细胞迁移能力，提示其在炎症反应中的调控功能。

4. **标题**：*ARL4A interacts with the IQGAP1 scaffolding protein in a GTP-dependent manner*

**作者**：Tanaka K, et al.

**摘要**：通过重组ARL4A蛋白的体外结合实验，发现其依赖GTP状态与IQGAP1结合，调控细胞骨架动态变化，影响细胞极性建立。

(注：以上文献为示例性内容，实际引用需根据具体研究检索PubMed等数据库获取。)

背景信息

**Background of ARL4A Recombinant Protein**

ARL4A (ADP-ribosylation factor-like 4A) is a small GTPase belonging to the ARF/ARL family, which plays critical roles in regulating intracellular trafficking, cytoskeletal dynamics, and cellular signaling. It is highly conserved across eukaryotes and shares structural homology with other ARF family members, characterized by a GTP-binding domain that cycles between active (GTP-bound) and inactive (GDP-bound) states. ARL4A is implicated in diverse cellular processes, including vesicle transport, membrane remodeling, and cell migration. Studies suggest its involvement in developmental pathways, particularly in neural and skeletal systems, as well as its potential link to diseases such as cancer and ciliopathies.

Recombinant ARL4A protein is engineered using molecular cloning techniques, where the ARL4A gene is expressed in heterologous systems like *E. coli* or mammalian cells. This allows large-scale production of the purified, functional protein for research applications. The recombinant form often includes tags (e.g., His-tag) for ease of purification via affinity chromatography and detection. Its production ensures high purity and consistency, enabling precise study of ARL4A’s biochemical properties, interactions with effector proteins (e.g., cytohesins), and regulatory mechanisms.

Research on recombinant ARL4A has advanced understanding of its GTPase activity, membrane association, and role in signaling pathways such as Wnt/β-catenin. It also serves as a tool for structural studies, drug screening, and exploring its therapeutic potential in ARL4A-dysregulated diseases. As a key molecular switch, ARL4A continues to be a focal point in deciphering cellular dynamics and disease mechanisms.